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AbstrACt
Introduction Belimumab, an anti-B-lymphocyte-
stimulator antibody, is approved for the treatment of active, 
autoantibody-positive systemic lupus erythematosus (SLE). 
Rituximab, a B cell-depleting anti-CD20 antibody, remains 
in the SLE treatment armamentarium despite failed trials 
in lupus nephritis and extrarenal lupus. These biologics, 
which operate through complementary mechanisms, might 
result in an enhanced depletion of circulating and tissue-
resident autoreactive B lymphocytes when administered 
together. Thus, belimumab and rituximab combination may 
be a highly effective treatment of SLE. This study aims to 
evaluate and compare the efficacy, safety and tolerability 
of subcutaneous (SC) belimumab and a single cycle of 
rituximab in patients with SLE with belimumab alone.
Methods and analysis BLISS-BELIEVE is a three-arm, 
randomised, double-blind, placebo-controlled, 104-week 
superiority study. Two hundred adults with SLE will be 
randomised 1:2:1 to arm A, belimumab SC 200 mg/
week for 52 weeks plus placebo at weeks 4 and 6; 
arm B, belimumab SC 200 mg/week for 52 weeks plus 
rituximab 1000 mg at weeks 4 and 6; arm C, belimumab 
SC 200 mg/week plus standard of care for 104 weeks. 
The 52-week treatment period (arms A and B) is followed 
by a 52-week observational phase. The primary efficacy 
endpoint is the proportion of patients with disease control 
(SLE Disease Activity Index (SLEDAI)−2K≤2, without 
immunosuppressants and with a prednisone-equivalent 
dose of ≤5 mg/day) at week 52. Major secondary 
efficacy endpoints are the proportion of patients in 
clinical remission (defined as SLEDAI-2K=0, without 
immunosuppressants and corticosteroids) at week 64, and 
the proportion of patients with disease control at week 
104. Safety endpoints include the incidence of adverse 
events (AEs), serious AEs and AEs of special interest.
Ethics and dissemination Within 6 months of the study’s 
primary manuscript publication, anonymised individual 
participant data and study documents can be requested 
for further research from www. clin ical stud ydat arequest. 
com.
trial registration number NCT03312907; Pre-results.
IntroduCtIon 
Immune-mediated inflammatory diseases 
(IMIDs) share some common molecular path-
ways that lead to inflammation, which results 
from dysregulation of the normal immune 
response. Chronic inflammation in IMIDs is 
associated with progressive tissue damage as 
well as increased comorbidity and mortality. 
Systemic lupus erythematosus (SLE) and 
strengths and limitations of this study
 ► This study builds on the experience of randomised 
controlled trials of the biologics belimumab and 
rituximab used as single agents, as well as preclin-
ical findings, case studies and open-label trials of 
belimumab and rituximab combination treatment.
 ► The unique sequence of treatment administration 
and assessment of the clinically relevant outcomes 
of disease control and disease remission are novel 
features of this study.
 ► BLISS-BELIEVE is the first randomised trial to car-
ry out observations for 52 weeks after stopping 
belimumab treatment, allowing for the assessment 
of true disease remission and its durability.
 ► BLISS-BELIEVE randomises patients to a third treat-
ment arm of belimumab plus standard-of-care ther-
apy to reflect current real-life practice.
 ► The study is limited by a relatively small sample 
size, and thus has limited power to detect infrequent 
adverse events.
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Sjögren’s syndrome are both prototypic antibody-depen-
dent IMIDs.1 SLE is a chronic multisystem inflammatory 
autoimmune disease associated with impaired health-re-
lated quality of life.2 3 The ultimate goals of SLE treat-
ment are disease remission, damage prevention (from 
both disease progression and prolonged use of medica-
tion) and normalisation of health-related quality of life.4 5 
These goals are difficult to achieve in most patients owing 
to limitations in the efficacy of, and long-term toxicity 
associated with, conventional treatments for SLE, such as 
corticosteroids and immunosuppressants.6 7 
Patients with SLE have elevated levels of circu-
lating B-lymphocyte stimulator (BLyS), a member of 
the tumour necrosis factor ligand superfamily that 
promotes B cell activation and differentiation.8–10 
Increased serum BLyS levels in patients with SLE are 
associated with disease activity, disease relapse and 
increased numbers of autoantibody-secreting plasma 
cells, linking BLyS to the pathogenesis of SLE.9 11  
Belimumab, a recombinant immunoglobulin G1λ 
human monoclonal antibody, binds to and antagonises 
the biological activity of soluble BLyS.12 It has shown 
efficacy in patients with autoantibody-positive active 
SLE in multiple trials.13–16 Belimumab-treated patients 
also experienced fewer disease flares, and showed a 
reduction in steroid use and long-term organ damage 
accrual compared with patients receiving standard of 
care (SoC).13–17 While the efficacy of belimumab has 
been demonstrated in patients with SLE, a proportion 
of patients maintain a degree of disease activity despite 
belimumab treatment.13–16 Therefore, additional effec-
tive and well-tolerated treatment options are required 
to further improve overall disease control.
Rituximab is a B cell-depleting, anti-CD20 monoclonal 
antibody that showed promise in several open-label clin-
ical studies,18–22 but failed to demonstrate efficacy in two 
randomised trials in SLE and lupus nephritis.23 24 In auto-
immune diseases, rituximab treatment results in rapid 
and near-complete depletion of circulating CD20+ B 
cells; however, relatively high numbers of B cells persist 
in tissues, such as bone marrow, kidneys, synovium and 
salivary glands.25–29 In SLE, an increase in BLyS levels 
after rituximab treatment may contribute to survival and 
rebound of autoreactive B cells and subsequent disease 
flares,30 31 as demonstrated in several cohort studies.32–34 
Consistent with these observations, reduced maturation 
of autoreactive B cells during B cell reconstitution was 
observed in mice treated with an agent that blocked B cell 
activating factor.35
Combining belimumab with rituximab therefore has 
a strong immunological rationale, as the drugs operate 
through complementary and perhaps synergistic mech-
anisms.36 Belimumab treatment results in the mobilisa-
tion of memory B cells from tissues despite an overall 
decrease in peripheral B cell levels.37 This phenom-
enon will render tissue-resident B cells more susceptible 
to depletion by rituximab. In addition, blocking the 
effects of high serum BLyS levels might have favourable 
quantitative and qualitative effects on B cell reconstitu-
tion after depletion.31 Synergistic or additive effects of 
such a combination have indeed been demonstrated in 
preclinical studies in lupus-prone mice. Improved tissue 
B cell subset depletion, a decrease in the levels of autoan-
tibodies, reduced proteinuria and improved survival were 
observed with combination therapy compared with either 
treatment alone.38–40
This hypothesis is further supported by case 
reports in patients with SLE, lupus nephritis and 
Sjögren’s syndrome,41–45 and prompted the SynBioSe 
study, which showed significant clinical and immunolog-
ical improvements from baseline in patients with refractory 
SLE who received rituximab and belimumab.46 Several 
clinical trials are currently investigating belimumab and 
rituximab combination therapy in primary Sjögren’s 
syndrome (NCT02631538), lupus nephritis (CALIBRATE; 
NCT02260934) and SLE (BEAT Lupus; ISRCTN47873003).
We hypothesised that durable low disease activity might 
be achieved in patients with active SLE by resetting the 
autoreactive humoral immune system. Therefore, we have 
designed the BLISS-BELIEVE study to examine whether 
combination treatment with belimumab and rituximab 
could induce a pre-defined state of disease control or 
disease remission, allowing the tapering of conventional 
SLE therapies. This study will employ a novel sequence 
of belimumab and rituximab combination therapy and 
investigate novel study endpoints, which could potentially 
shift the current paradigm of SLE treatment.
The objective of this study is to evaluate the efficacy, 
safety and tolerability of subcutaneous (SC) belimumab 
and a single cycle of rituximab administered in a combi-




This is a phase III, multicentre, three-arm, randomised, 
double-blind, placebo-controlled, 104-week superi-
ority study (BEL205646; NCT03312907). There will be 
a 52-week double-blind treatment period followed by 
a 52-week double-blind observational treatment-free 
follow-up period in arms A and B (to week 104) (figure 1). 
The study began recruitment in March 2018, with an esti-
mated final completion in June 2021.
study population
Detailed inclusion and exclusion criteria are listed in 
box 1. Briefly, patients must be ≥18 years of age, with a clin-
ical diagnosis of SLE according to the American College 
of Rheumatology criteria, and an SLE Disease Activity 
Index (SLEDAI)-2K score ≥6 at screening. Patients with 
severe lupus nephritis or severe active central nervous 
system lupus will be excluded. Informed consent will be 
obtained from patients prior to the initiation of any study 
procedures or study-specific data collection.
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randomisation
Patients will be randomised 1:2:1 to one of three treat-
ment arms: belimumab plus placebo (arm A, control), 
belimumab plus rituximab (arm B, combination) or 
belimumab plus SoC (arm C, reference). At rando-
misation, patients will be stratified by their screening 
SLEDAI-2K score (≤9 vs ≥10), immunosuppressant use 
(immunosuppressant use vs no use) and corticosteroid 
dose (prednisone equivalent ≤10 mg/day vs >10 mg/day). 
Randomisation, and the first dose of belimumab, should 
be completed within 35 days of the initiation of screening.
blinding
The study is double-blind with regards to whether partici-
pants are randomised to arm A or arm B. Randomisation 
to arm C will not be blinded. To minimise bias given that 
arm C is open-label, independent assessors blinded to 
treatment group will conduct the SLEDAI-2K assessments 
at selected visits for the primary and major secondary effi-
cacy endpoints. Unblinded safety data will be reviewed 
regularly by an independent data monitoring committee.
study treatments
Patients randomised to arm A (control) will receive 
belimumab SC 200 mg/week for 52 weeks with a cycle 
of intravenous placebo (rituximab-matched; dose 1 
at week 4 and dose 2 at week 6). Patients randomised 
to arm B (combination) will receive belimumab SC 
200 mg/week for 52 weeks with a cycle of rituximab 
intravenously (1000 mg doses given at week 4 and 
week 6). Patients randomised to arm C (reference) 
will receive belimumab SC 200 mg/week plus SoC, 
including immunosuppressants, for 104 weeks. Patients 
in arms A and B will be administered a premedication 
regimen 30 min before each placebo or rituximab 
infusion, consisting of methylprednisolone intrave-
nously 100 mg or equivalent, an oral antihistamine and 
acetaminophen or equivalent (table 1).
After completing week 52, patients in arms A and B 
will enter into the 52-week treatment-free (defined as 
no active treatment with belimumab and/or rituximab), 
observational phase of the study (weeks 53 through 104). 
Patients in arm C will continue to receive belimumab 
SC and stable immunosuppressants during this phase. 
In addition, treatment with antimalarials, non-steroidal 
anti-inflammatory drugs and corticosteroids (prednisone 
equivalent ≤5 mg/day) is allowed in the observational 
phase in all three arms.
Patients considered treatment failures (patients in arm 
A or B who fail to respond adequately to study treatment, 
who do not meet the corticosteroid taper rules or tolerate 
immunosuppressant withdrawal at week 4, or who require 
additional therapy) will be encouraged to remain in the 
study to receive all safety and efficacy assessments through 
week 104. During this time (weeks 53–104), additional 
treatment may be given, if deemed of benefit by the inves-
tigator, to patients with responses that do not reach the 
predefined study criteria for disease control (as defined 
in the study endpoints), or subsequently experience 
increased disease activity. This treatment can include 
belimumab, corticosteroids, and/or immunosup-
pressants; additional treatment with rituximab will be 
permitted, but not encouraged.
Concomitant medications
Patients randomised to arms A and B who enter the study 
on immunosuppressants will discontinue immunosup-
pressants at or prior to the week 4 visit. Patients in arm 
C who enter the study on stable immunosuppressants 
may continue to receive them throughout the study. 
After the initial 12 weeks of study treatment, a proto-
col-specified corticosteroid taper will be initiated for all 
three arms (carried out under the direction of the inves-
tigator), with a target of reaching a prednisone equiva-
lent dose of ≤5 mg/day by week 26. After week 26, if a 
patient’s average daily corticosteroid dose exceeds 5 mg/
day prednisone equivalent, the patient will be declared a 
treatment failure. Antimalarials and non-steroidal anti-in-
flammatory drugs may be used throughout the study for 
all treatment arms.
Figure 1 Study design. IV, intravenous; PBO, placebo; RTX, rituximab; SC, subcutaneous; SoC, standard of care; W, week. 
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Other investigational agents (or co-enrolment into 
another study of a different investigational agent), antitu-
mour necrosis factor therapy, other biologics with effects 
on the immune system, immunoglobulin intravenously, 
cyclophosphamide intravenously and plasmapheresis 
are prohibited throughout the study.
study endpoints
The primary efficacy endpoint is the proportion of 
patients with disease control at week 52, defined as a 
SLEDAI-2K score of ≤2, achieved without immuno-
suppressants and with a prednisone equivalent dose 
of ≤5 mg/day. The major secondary efficacy endpoints are 
the proportion of patients in clinical remission at week 
64 (defined as a clinical SLEDAI-2K score of 0, allowing 
for serologies of anti-dsDNA and hypocomplementaemia 
and achieved without immunosuppressants and corti-
costeroids), and the proportion of patients with disease 
control at week 104 (defined as a SLEDAI-2K score of ≤2, 
achieved without immunosuppressants and with a pred-
nisone-equivalent dose of ≤5 mg/day). Patient-reported 
outcome measures include change from baseline in 
Patient Global Assessment (PtGA), LupusQoL domain 
summary scores and Functional Assessment of Chronic 
Illness Therapy (FACIT)-Fatigue score, and proportion 
of patients with an improvement in FACIT-Fatigue score 
exceeding the minimal clinically-important difference. 
Safety endpoints include the incidence of adverse events 
(AEs), including serious AEs (SAEs) and AEs of special 
interest (AESI). The endpoints will be assessed using the 
measures listed in box 2.
sample size calculation
Approximately 400 patients will be screened, with a 
goal of randomising at least 200 patients (50% screen 
failure rate). A target of 50 patients will be randomised 
in arms A and C, and 100 patients in arm B. This sample 
size provides at least 95% power (for the comparison of 
arm B to arm A at week 52) at a 5% level of significance, 
assuming the underlying response in the control arm is 
10%, and the true population effect is ≥25% with treat-
ment arm B (assumed response rate of 35%). For the 
primary endpoint, patients who drop out from the study 
will be included in the analysis as non-responders; thus, 
the assumed responder rates for arms A and B already 
account for the rate of patient dropout. However, to 
ensure adequate safety exposure in arm B, the sample size 
may be increased up to 300 patients if the dropout rate 
reaches 10% at the scheduled time point for receiving 
both doses of placebo or rituximab.
Based on limited clinical data with therapies including 
both belimumab and rituximab, opinions from external 
experts, and the rarity of remission or disease control 
seen in published studies, a rate of 35% of patients in 
arm B achieving a state of disease control is considered 
to be highly clinically significant in SLE care. A response 
rate of 10% at week 52 was assumed for arm A (control), 
based on historical data from three belimumab phase 
box 1 Patient inclusion and exclusion criteria
Inclusion criteria
 ► ≥18 years of age
 ► Clinical diagnosis of SLE according to the ACR criteria
 ► Minimum screening SLEDAI-2K score ≥6
 ► Unequivocally positive ANA and/or anti-dsDNA test results from two 
independent time points
 ► Stable SLE treatment regimen
 ► Female patients who are not pregnant, not breastfeeding, not of 
childbearing potential or follow contraceptive guidance
Exclusion criteria
 ► Symptomatic herpes zoster within 3 months prior to screening
 ► Active or latent TB, confirmed by medical history and examination, 
chest X-rays and TB testing: either a positive TST (defined as a skin 
induration ≥5 mm at 48–72 hours, regardless of BCG or other vacci-
nation history), or a positive QuantiFERON-TB Gold test
 ► Allergies to humanised monoclonal antibodies
 ► Clinically significant multiple or severe drug allergies and/or history 
of hypersensitivity to belimumab and/or rituximab
 ► Lymphoma, leukaemia, or any malignancy within the past 5 years
 ► ALT >2 x ULN
 ► Bilirubin >1.5 x ULN
 ► IgA <10 mg/dL
 ► IgG <250 mg/dL
 ► Neutrophils <1.5×109
 ► Unstable liver or biliary disease
 ► Severe heart failure
 ► QTc>450 msec or>480 ms in patients with bundle branch block
 ► History of a major organ transplant
 ► Clinical evidence of significant unstable or uncontrolled acute or 
chronic diseases not due to SLE
 ► Acute or chronic infection requiring management
 ► Severe lupus kidney disease
 ► Severe active central nervous system lupus
 ► Planned surgical procedure, laboratory abnormality or condition that 
makes the patient unsuitable for the study
 ► Evidence of serious suicide risk
 ► History of an anaphylaxis reaction to parenteral administration of 
contrast agents, human/murine protein, or monoclonal antibodies
 ► Live vaccine(s) within 1 month prior to screening
 ► Within 364 days of day 1, received certain biologics (belimumab, 
rituximab, abatacept, a B cell-targeted therapy, a biological investi-
gational agent other than B cell-targeted therapy), or required three 
or more courses of systemic corticosteroids
 ► Within 90 days of day 1, received anti-TNF therapy, interleukin-1 
receptor antagonist, intravenous immunoglobulin, high-dose pred-
nisone or equivalent, or plasmapheresis
 ► Within 60 days of day 1, received a non-biological investigational 
agent, intravenous cyclophosphamide, a steroid injection
 ► Positive HIV antibody test
 ► Positive serology for hepatitis B or hepatitis C
 ► Current or history (within 364 days of day 1) of drug/alcohol 
dependence
 ► Sensitivity to any of the study treatments or components
 ► Unable to administer belimumab by SC injection
ACR, American College of Rheumatology; ALT, alanine aminotransferase; 
ANA, anti-nuclear antibodies; BCG, Bacillus Calmette-Guerin; HIV, human 
immunodeficiency virus; IgA, immunoglobulin A; IgG, immunoglobulin G; QTc, 
corrected QT; SC, subcutaneous; SLE, systemic lupus erythematosus; SLEDAI-
2K, SLE Disease Activity Index; TB, tuberculosis; TNF, tumour necrosis factor; 
TST, tuberculin skin test; ULN, upper limit of normal.
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III trials. Assuming a 10% control responder rate and 
50 patients in arm A and 100 patients in arm B, the 
minimum detectable effect at p<0.05 is a 12% improve-
ment (ie, an observed improvement of 12% or more in 
arm B would give a p<0.05). A sample size sensitivity anal-
ysis was conducted on the primary endpoint to investigate 
the impact on power if the assumed underlying control 
response rate deviates from 10% or the treatment differ-
ence deviates from 25%.
statistical analyses
Unless otherwise stated, all analyses will be performed 
on the intent-to-treat population. The key analyses will 
compare belimumab with or without a single cycle of 
rituximab (arm A vs arm B). Descriptive statistics will be 
used to compare the combination of belimumab with 
a single cycle of rituximab (arm B) versus belimumab 
with SoC (arm C). The primary and major secondary 
endpoints will be compared using a logistic regression 
model. The independent variables will include treatment 
group, baseline SLEDAI-2K score (≤9 vs ≥10), immuno-
suppressant use at baseline (immunosuppressant use vs 
no use), and baseline corticosteroid dose (prednisone 
equivalent ≤10 mg/day vs >10 mg/day). If any factor fails 
to converge it will be removed from the logistic model. If 
the model fails to converge (eg, owing to a small number 
of responders), the endpoints will be analysed using a 
Fisher’s exact test. Missing data are accounted for in the 
primary efficacy endpoint, as all patients will be classified 
as either a non-responder (including premature study 
discontinuation or treatment failure prior to week 52) 
or responder. Sensitivity analyses will be used to explore 
the impact of missing data and treatment failure impu-
tation. Descriptive statistics will be used to summarise 
AEs, SAEs, AESI, changes in laboratory parameters, and 
immunogenicity.
Ethical considerations
This study will be conducted in accordance with consensus 
ethical principles derived from international guidelines, 
including the Declaration of Helsinki and Council for 
International Organisations of Medical Sciences Inter-
national Ethical Guidelines, applicable International 
Conference on Harmonisation Good Clinical Practice 
Guidelines and applicable laws and regulations. SAEs will 
Table 1 Study treatment arms








200 mg/week plus SoC 
for 104 weeks
Rituximab or matched 
placebo
One cycle of placebo intravenously 
(rituximab-matched) at week 4 and 
week 6
One cycle of rituximab intravenously 
1000 mg at week 4 and week 6
None
Premedication (30 min 
before each placebo or 
rituximab infusion)
Methylprednisolone intravenously 
100 mg or equivalent, oral 
antihistamine, acetaminophen or 
equivalent
Methylprednisolone intravenously 
100 mg or equivalent, oral 
antihistamine, acetaminophen or 
equivalent
None
Post week 52 therapy Antimalarials,
NSAIDs and/or corticosteroids with a 
prednisone equivalent dose of ≤5 mg/
day
Antimalarials,
NSAIDs and/or corticosteroids 




200 mg/week plus 
SoC*
*Patients in arm C are allowed to receive rescue therapy if, in the opinion of the investigator, they require additional treatment. This can 
include corticosteroids at >5 mg/day prednisone equivalent.
NSAIDs, non-steroidal anti-inflammatory drugs; SC, subcutaneous; SoC, standard of care.
box 2 study assessments
Efficacy assessment
SLEDAI-2K, a clinical index for measuring SLE disease activity in the 
previous 10 days, at screening/baseline and at weeks 52, 64 and 104.
safety assessment
Full physical examination, ECG, clinical safety laboratory assess-
ments, neurological assessment, and suicidal risk monitoring 
(assessed via C-SSRS) at screening. Symptom-driven physical exam-
ination, vital signs, clinical safety laboratory assessments, neurological 
assessment, and suicidal risk monitoring at scheduled and unscheduled 
visits.
laboratory tests
Anti-dsDNA/ANA, complement C3/C4, serum immunoglobulin (IgG, IgA, 
IgM), urine testing (urinalysis, spot urine protein), haematology and 
blood chemistry, pregnancy test: performed at screening and at each 
assessment visit. Autoantibody levels, including aCL, beta-2-glycopro-
tein, lupus anticoagulant, and extractable nuclear antigens, will be mea-
sured at day 1 and weeks 8, 26, 52, 60, 80 and 104.
b cell analyses
Pharmacokinetics
aCL, anticardiolipin; ANA, antinuclear antibodies; C, complement; C-SSRS, 
Columbia-Suicide Severity Rating Scale; ECG, electrocardiogram; Ig, 
immunoglobulin; SLE, systemic lupus erythematosus; SLEDAI, SLE Disease 
Activity Index.
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be reported by the investigator to the sponsor immedi-
ately, and no later than within 24 hours. Written informed 
consent will be obtained from all patients, who will be 
assigned a unique identifier; all patient records and data 
transferred to the sponsor will contain the identifier only.
dissemination
Study information will be publicly available at www. 
clinicaltrials. gov, and the results of this trial (positive 
and negative) will be submitted for publication in rele-
vant peer-reviewed publications and the key findings 
presented at national and international conferences. 
Within 6 months of the publication of the primary manu-
script for this study, anonymised individual participant 
data, the annotated case report form, protocol, reporting 
and analysis plan, data set specifications, raw data set, 
analysis-ready data set and clinical study report will be 
available for research proposals approved by an indepen-
dent review committee. Proposals should be submitted to 
www. clin ical stud ydat arequest. com. A data access agree-
ment will be required. This paper complies with the 
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) recommendations for protocol 
reporting.47
Patient and public involvement
Patients and/or public were not involved in the develop-
ment of this study.
dIsCussIon
This study aims to explore the potential for synergy 
and to demonstrate greater efficacy of combination 
treatment with belimumab and rituximab compared 
with belimumab monotherapy in achieving low disease 
activity, disease remission, or clinical quiescence in 
patients with SLE. Although to date, combination 
biologics have not been widely used in other diseases, we 
think there is a strong immunological rationale to study 
belimumab and rituximab combination therapy in the 
context of SLE. The residual disease activity that many 
patients with SLE experience despite current therapies 
further justifies the exploration of this novel combina-
tion treatment. If this study confirms our hypothesis 
that combined belimumab and rituximab treatment has 
additional efficacy over standard belimumab care, then 
this may transform the current treatment paradigm, 
allowing patients with SLE to discontinue conventional, 
often toxic medications.
The unique sequence of administering belimumab 
and rituximab (which we believe will enhance B cell 
depletion), the use of belimumab SC and a larger sample 
size, differentiate the BLISS-BELIEVE study from BEAT 
Lupus (ISRCTN47873003),48 a similar belimumab and 
rituximab combination therapy, phase II trial in SLE that 
is currently recruiting patients in the UK. The sequence 
of treatment administration also differs from that used in 
the CALIBRATE trial in lupus nephritis (NCT02260934).49 
In addition, BLISS-BELIEVE is one of the first trials of 
belimumab to carry out assessments for 52 weeks after stop-
ping treatment, and investigate ambitious, clinically rele-
vant outcomes of low disease activity or disease remission. 
The 52-week observational, treatment-free phase provides 
an opportunity to observe if a true disease remission occurs, 
and allows for the assessment of the durability of any such 
remission or low disease activity. In the treatment of SLE, it 
is important to balance clinical efficacy and therapy-related 
toxicity. The unique design of BLISS-BELIEVE will ensure 
this is assessed through the use of rigorous endpoints (such 
as clinical remission), and by enabling the termination of 
belimumab if toxicity is an issue.
The unique treatment schedules were selected 
according to a rationale based on the current evidence. In 
the 52-week treatment phase, belimumab SC 200 mg will 
be administered weekly as per the treatment regimen in 
the phase III study of belimumab SC, which demonstrated 
its safety and efficacy in patients with SLE.15 Rituximab 
is not approved for the treatment of patients with SLE, 
and no standard dosing regimen has been established. 
Based on previous trials of rituximab that showed a lack 
of efficacy, we deemed that a rituximab-only arm would 
fail to meet standards of equipoise. In the current study, 
rituximab dosing will follow one cycle of the approved 
dosing recommendation for rheumatoid arthritis, which 
is two doses of 1000 mg intravenously given 2 weeks apart. 
In a phase II/III trial, this rituximab regimen demon-
strated rapid depletion of CD19-positive cells (<5 cells/
µL) in the majority of patients with SLE.23 It is also the 
dosing regimen recommended in NHS England’s Interim 
Clinical Commissioning Policy Statement for rituximab 
use in patients with refractory SLE.50 Furthermore, 
belimumab and rituximab combination treatment has 
previously shown acceptable safety and significant clinical 
responses in patients with severe, refractory SLE.46
Separating the administration of belimumab and 
rituximab may allow for observation of safety events 
attributable to each treatment; however, owing to the 
relatively small sample size, the study will have limited 
power to detect less common AEs. With the consecutive 
administration regimen, the study allows investigation 
of the hypothesis that belimumab mobilises additional 
CD20+ B cells into the circulation, making them available 
for anti-CD20 treatment with rituximab. Therefore, we 
will be able to further establish whether more efficient 
depletion of autoreactive B cells, otherwise protected 
from cell death in the tissue niches, is achieved.37 We 
anticipate that there will be fewer autoreactive B cells 
appearing in the memory B cell compartment during 
the early phase of B cell reconstitution. However, we are 
aware that the controls for this analysis are historical, 
owing to the ethical considerations discussed above. 
B cell mobilisation will be evaluated by comparing base-
line, pre-belimumab B cell levels with autoreactive B 
cells appearing in peripheral blood after belimumab 
treatment. The possible reappearance of autoreac-
tive B cells following rituximab treatment will then be 
7Teng YKO, et al. BMJ Open 2019;9:e025687. doi:10.1136/bmjopen-2018-025687
Open access
established by comparing B cells levels between the 
belimumab-only and belimumab and rituximab arms.
This study has some limitations. Because rituximab 
is not approved for the treatment of patients with 
SLE, a rituximab-only arm could not be included in 
the protocol. Therefore, some clinical and serological 
outcomes attributable to rituximab treatment will not 
be assessed. However, this study aims to explore whether 
belimumab treatment can be optimised by sequential 
treatment with rituximab, for which a rituximab-only 
arm is not required. Another limitation of the study 
design is that direct measurements of B cell deple-
tion in tissue niches will not be performed. However, 
this measurement and a rituximab-only arm are being 
explored in a clinical trial of belimumab and rituximab 
combination therapy in primary Sjögren’s syndrome 
(NCT02631538), which follows a similar administration 
regimen. Another concern is that patients in study arms 
A and B will discontinue immunosuppressants from 
week 4, which might result in a higher than predicted 
treatment failure rate, due to flares occurring before 
belimumab and rituximab achieve therapeutic efficacy 
at week 12. However, the risk of disease flares to patients 
will be mitigated by methylprednisolone pretreatment 
and the option for investigators to adjust concomitant 
corticosteroid treatment as clinically necessary up to 
week 26. Although substantially different from previous 
belimumab trials, such as BLISS-76, in which more than 
half the patients continued on background immuno-
suppressive agents,12 this regimen will allow investiga-
tion of whether belimumab and rituximab combination 
therapy could result in an immunologically more favour-
able condition in some patients, thus enabling the 
tapering of conventional immunosuppressive drugs 
and possibly an immunosuppressant-free honeymoon. 
A positive outcome of BLISS-BELIEVE would further 
support the rationale to test this therapeutic strategy in 
Sjögren’s syndrome and other autoantibody-dependent 
IMIDs.
In conclusion, the BLISS-BELIEVE study is supported 
by strong scientific rationale from preclinical studies, case 
reports and open-label trials. Its pioneering and unique 
design will allow for a long-term observation of true 
clinical remission, assessment of the durability of such 
a remission state and assessment of any potential safety 
issues. The results of this study may support the rationale 
for combination therapy in other autoimmune condi-
tions. BLISS-BELIEVE began recruitment in March 2018, 
with estimated study completion in June 2021.
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